Matrix metalloproteinase-3 as a marker of subclinical activity in rheumatoid arthritis patients: Relation to ultrasonographic activity

被引:4
|
作者
Hamdy, Fatma [1 ]
Morad, Nibal [1 ]
Tharwat, Samar [1 ]
Abd El-khalek, Ahmed [2 ]
Mahsoub, Nancy [3 ]
Eltoraby, Ehab [1 ]
Enein, Asmaa [1 ]
机构
[1] Mansoura Univ, Fac Med, Internal Med Dept, Rheumatol & Immunol Unit, Dakahlia, Egypt
[2] Mansoura Univ, Fac Med, Diagnost Radiol Dept, Dakahlia, Egypt
[3] Mansoura Univ, Fac Med, Clin Pathol Dept, Dakahlia, Egypt
来源
EGYPTIAN RHEUMATOLOGIST | 2022年 / 44卷 / 03期
关键词
Rheumatoid arthritis; Remission; Subclinical activity; Matrix metalloproteinase-3; Sonographic activity; DISEASE-ACTIVITY;
D O I
10.1016/j.ejr.2021.12.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Rheumatoid arthritis (RA) isa chronic disease which may result in progressive joint destruc-tion even with clinical remission. Ultrasound (US) can detect subclinical disease activity and matrix met-alloproteinase 3 (MMP-3) has a role in disease activity in RA. Aim of the work: To evaluate the level of MMP-3 in RA patients and its ability to predict sonographic activ-ity in patients with clinical remission or low disease activity (LDA). Patients and methods: This study included 45 RA patients with a disease activity score (DAS28) <3.2 and 45 matched healthy control. US evaluation using modified German US7 score was performed and accord-ingly patients were classified into those with sonographic remission (grey scale 0-1) or activity. MMP-3 level was assessed by enzyme-linked immunosorbent assay. Results. The mean age of the patients was 45 +/- 9.5 years and 86.7% were females. Sonographic remission was achieved in 20 (44.4 %) patients. There was a significant difference in serum MMP-3 between patients and control (17 +/- 4.5 vs 6.3 +/- 2.2 ng/ml; p < 0.0001). There was no difference between patients with clinical remission (n = 37) and those with LDA (n = 8). Serum MMP-3 tended to be higher in patients with sono-graphic activity than in those with sonographic remission (18 +/- 5.3 vs 15.6 +/- 2.8 ng/ml; p = 0.3). Serum MMP-3 significantly correlated with erythrocyte sedimentation rate (p = 0.002) and synovitis score (p = 0.002). Conclusion: Serum MMP-3 was higher in RA patients than in control and was associated with the ultra -sound synovitis score. However, serum MMP-3 was not able to differentiate patients with sonographic remission from those with subclinical activity. (c) 2022 Egyptian Society of Rheumatic Diseases. Publishing services provided by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:261 / 265
页数:5
相关论文
共 50 条
  • [31] Serum matrix metalloproteinase-3 in patients with psoriasis with and without arthritis
    Taha, Alsayeda A. A.
    Khadr, Nouran A.
    Elneily, Dalia A. E.
    Elkhalifa, Marwa S. A.
    Mohamad, Sara S. M.
    JOURNAL OF EGYPTIAN WOMENS DERMATOLOGICAL SOCIETY, 2023, 20 (02): : 125 - 130
  • [32] Matrix metalloproteinase-3 gene polymorphism and its mRNA expression in rheumatoid arthritis
    Ma, M. J.
    Liu, H. C.
    Qu, X. Q.
    Wang, J. L.
    GENETICS AND MOLECULAR RESEARCH, 2015, 14 (04) : 15652 - 15659
  • [33] SCAVENGER RECEPTOR EXPRESSION, GLYCATION, AND MATRIX METALLOPROTEINASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Huang, W. -N.
    Tso, T. K.
    Wu, H. -C.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 591 - 591
  • [34] Serum matrix metalloproteinase-3 levels in rheumatoid arthritis and inflammatory diseases without arthritis; Correlation with clinical and laboratory indices of disease activity.
    Sugiyama, E
    Taki, H
    Shinoda, K
    Harada, S
    Kobayashi, M
    ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S184 - S184
  • [35] ASSESSMENT OF MATRIX METALLOPROTEINASE-3 IN SPONDYLOARTHRITIS: CORRELATION WITH DISEASE ACTIVITY
    Slouma, M.
    Bouzid, S.
    Kharrat, L.
    Tezeghdenti, A.
    Ghazouani, E.
    Metoui, L.
    Dhahri, R.
    Gharsallah, I.
    Louzir, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1718 - 1719
  • [36] Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis
    Avdeeva, A. S.
    Aleksandrova, E. N.
    Novikov, A. A.
    Cherkasova, M. V.
    Panasyuk, E. Yu.
    Nasonov, E. L.
    TERAPEVTICHESKII ARKHIV, 2013, 85 (05) : 24 - 29
  • [37] Omentin concentrations are independently associated with those of matrix metalloproteinase-3 in patients with mild but not severe rheumatoid arthritis
    Robinson, Chanel
    Tsang, Linda
    Solomon, Ahmed
    Woodiwiss, Angela J.
    Gunter, Sule
    Millen, Aletta M. E.
    Norton, Gavin R.
    Fernandez-Lopez, Maria J.
    Hollan, Ivana
    Dessein, Patrick H.
    RHEUMATOLOGY INTERNATIONAL, 2017, 37 (01) : 3 - 11
  • [38] Omentin concentrations are independently associated with those of matrix metalloproteinase-3 in patients with mild but not severe rheumatoid arthritis
    Chanel Robinson
    Linda Tsang
    Ahmed Solomon
    Angela J. Woodiwiss
    Sule Gunter
    Aletta M. E. Millen
    Gavin R. Norton
    Maria J. Fernandez-Lopez
    Ivana Hollan
    Patrick H. Dessein
    Rheumatology International, 2017, 37 : 3 - 11
  • [39] Association of heterogeneity of the thyroid gland with matrix metalloproteinase-3 in rheumatoid arthritis patients with Hashimoto's thyroiditis
    Nagasaki, Toshiki
    Nagata, Yuki
    Wakita, Yosuke
    Yamada, Shinsuke
    Goto, Hitoshi
    Imanishi, Yasuo
    Onoda, Naoyoshi
    Emoto, Masanori
    Inaba, Masaaki
    MINERVA ENDOCRINOLOGICA, 2018, 43 (04) : 398 - 405
  • [40] Improvement in matrix metalloproteinase-3 independently predicts low disease activity at 52 weeks in bio-switch rheumatoid arthritis patients treated with abatacept
    Takemoto, T.
    Takahashi, N.
    Kida, D.
    Kaneko, A.
    Hirano, Y.
    Fujibayashi, T.
    Kanayama, Y.
    Hanabayashi, M.
    Yabe, Y.
    Takagi, H.
    Oguchi, T.
    Kato, T.
    Funahashi, K.
    Matsumoto, T.
    Sobue, Y.
    Nishiume, T.
    Suzuki, M.
    Yokota, Y.
    Terabe, K.
    Asai, S.
    Ishiguro, N.
    Kojima, T.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2020, 38 (05) : 933 - 939